Skip to main navigation
Skip to main content
Denali Therapeutics
  • Home
  • Scientific Approach
    • GENETIC PATHWAY POTENTIAL
    • ENGINEERING BRAIN DELIVERY
    • BIOMARKER-DRIVEN DEVELOPMENT
    • PUBLICATIONS
  • Pipeline
  • Patients
  • Investor & Media Relations
    • Press Releases
    • Events
    • SEC Filings
    • Corporate Governance
    • Analyst Coverage
  • Leadership
  • Partnering
  • Careers
    • Job Openings
    • STEM Outreach Overview
    • Student Internships
    • Postdoc Program
  • Contact

SEC Filings

Sign Up For Updates
Filing date Form Description View
Jul 07, 2025 8-K Report of unscheduled material events or corporate event View HTML
0001714899-25-000146.pdf
0001714899-25-000146.rtf
0001714899-25-000146.xls
Jun 05, 2025 4 Statement of changes in beneficial ownership of securities View HTML
0001714899-25-000136.pdf
0001714899-25-000136.rtf
0001714899-25-000136.xls
Jun 05, 2025 4 Statement of changes in beneficial ownership of securities View HTML
0001714899-25-000137.pdf
0001714899-25-000137.rtf
0001714899-25-000137.xls
Jun 05, 2025 4 Statement of changes in beneficial ownership of securities View HTML
0001714899-25-000138.pdf
0001714899-25-000138.rtf
0001714899-25-000138.xls
Jun 05, 2025 4 Statement of changes in beneficial ownership of securities View HTML
0001714899-25-000139.pdf
0001714899-25-000139.rtf
0001714899-25-000139.xls
Jun 05, 2025 4 Statement of changes in beneficial ownership of securities View HTML
0001714899-25-000140.pdf
0001714899-25-000140.rtf
0001714899-25-000140.xls
Jun 05, 2025 4 Statement of changes in beneficial ownership of securities View HTML
0001714899-25-000141.pdf
0001714899-25-000141.rtf
0001714899-25-000141.xls
Jun 05, 2025 4 Statement of changes in beneficial ownership of securities View HTML
0001714899-25-000142.pdf
0001714899-25-000142.rtf
0001714899-25-000142.xls
Jun 05, 2025 3 Initial filing by director officer or owner of more than ten percent View HTML
0000950170-25-082442.pdf
0000950170-25-082442.rtf
0000950170-25-082442.xls
Jun 05, 2025 3 Initial filing by director officer or owner of more than ten percent View HTML
0000950170-25-082455.pdf
0000950170-25-082455.rtf
0000950170-25-082455.xls
Pagination
  • Current page 1
  • Page 2
  • Page 3
  • …
  • Next page ›
  • Last page »
Displaying 1 - 10 of 708 results

Sign up for email alerts

Stay in the loop with updates on the latest Denali news delivered right to your inbox


  • Investor & Media Relations

CONTACT US

161 Oyster Point Blvd- South San Francisco, CA 94080

© 2025 Denali Therapeutics

  • Privacy Policy
  • Terms of Use

©2025 Denali Therapeutics | 161 Oyster Point Boulevard, South San Francisco, CA 94080

  • Privacy Policy
  • Terms of Use